Advertisement

Clinical Rheumatology

, Volume 33, Issue 8, pp 1183–1184 | Cite as

Two Takayasu arteritis patients successfully treated with rituximab

  • E. Caltran
  • G. Di Colo
  • G. Ghigliotti
  • R. Capecchi
  • E. Catarsi
  • I. Puxeddu
  • P. Migliorini
  • A. Tavoni
Case Based Review

Abstract

Takayasu arteritis (TA) is a rare form of chronic large vessel vasculitis of unknown origin involving the aorta and its major branches. Recently, the involvement of B lymphocytes in TA has been suggested, and active refractory TA patients were successfully treated with B cell depletion therapy (BCDT). We report two cases of patients with TA successfully treated with anti-CD20 monoclonal antibody (rituximab). The favorable outcome of rituximab treatment in our patients also support the view that BCDT can be a useful option for refractory TA, and its potential should be evaluated in controlled trials.

Keywords

B lymphocytes Rituximab Takayasu arteritis 

Notes

Disclosures

None.

References

  1. 1.
    Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z (2011) Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev 11:61–67PubMedCrossRefGoogle Scholar
  2. 2.
    Sima D, Thiele B, Turowski A, Wilke K, Hiepe F, Volk D et al (1994) Anti-endothelial antibodies in Takayasu arteritis. Arthritis Rheum 37:441–443PubMedCrossRefGoogle Scholar
  3. 3.
    Inder SJ, Bobryshev YV, Cherian SM, Wang AY, Lord RS, Masuda K et al (2000) Immunophenotypic analysis of the aortic wall in Takayasu’s arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno- inflammatory reactions. Cardiovasc Surg 8:141–148PubMedCrossRefGoogle Scholar
  4. 4.
    Sharma BK, Jain S, Suri S, Numano F (1996) Diagnostic criteria for Takayasu arteritis. Int J Cardiol 54:S141–S147PubMedCrossRefGoogle Scholar
  5. 5.
    Comarmond C, Plaisier E, Dahan K, Mirault T, Emmerich J, Amoura Z et al (2012) Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev 11:678–684PubMedCrossRefGoogle Scholar
  6. 6.
    Quartuccio L, Schiavon F, Zuliani F, Carraro V, Catarsi E, Tavoni AG et al (2012) Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol 30(6):922–928PubMedGoogle Scholar
  7. 7.
    Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50:2296–2304PubMedCrossRefGoogle Scholar
  8. 8.
    Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L et al (2012) Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology 51:151–156PubMedCrossRefGoogle Scholar
  9. 9.
    Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T (2008) Successful treatment of a patient with Takayasu arteritis using a humanized anti interleukin-6 receptor antibody. Arthritis Rheum 58:1197–1200PubMedCrossRefGoogle Scholar
  10. 10.
    Galarza C, Valencia D, Tobón GJ, Zurita L, Mantilla RD, Pineda-Tamayo R et al (2008) Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol 34:124–128PubMedCrossRefGoogle Scholar
  11. 11.
    Hoyer BF, Mumtaz IM, Loddenkemper K, Bruns A, Sengler C, Hermann KG et al (2012) Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 71:75–79PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2014

Authors and Affiliations

  • E. Caltran
    • 1
  • G. Di Colo
    • 1
  • G. Ghigliotti
    • 2
  • R. Capecchi
    • 1
  • E. Catarsi
    • 1
  • I. Puxeddu
    • 1
  • P. Migliorini
    • 1
  • A. Tavoni
    • 1
  1. 1.Clinical Immunology Unit, Department of Clinical and Experimental MedicineUniversity of PisaPisaItaly
  2. 2.Cardiology Unit, Internal Medicine DepartmentUniversity of GenovaGenovaItaly

Personalised recommendations